Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Stocks in this Quantisnow insightHealth Care
Historical context for KRRO
Across the 12 sessions after earlier KRRO headlines, the stock closed higher 7 times and lower 5 times, with a median move of 6.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | KRRO | SPY |
|---|---|---|---|
| May 7, 2026 | Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update | -3.4% | -0.3% |
| May 6, 2026 | Korro to Participate in Upcoming Investor Conferences | +6.0% | +1.4% |
| Apr 16, 2026 | Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences | -1.5% | +0.2% |
| Apr 13, 2026 | Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | +8.0% | +1.0% |
| Mar 13, 2026 | Korro Bio upgraded by Raymond James with a new price targetand 1 other headline that session | +11.3% | -0.6% |
| Feb 26, 2026 | Korro to Present at the TD Cowen 46th Annual Health Care Conference | -0.3% | -0.6% |
Quantisnow market dataNASDAQ
KRRO
Korro Bio Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2019
Get push alerts for KRRO
Full KRRO profile on Quantisnow Follow KRRO and get a push notification the moment its next story breaks.